Table 4.

Univariate and multivariate Cox regression analysis for PFS and OS in advanced stage epithelial ovarian patients

	PFS				OS
	Univariate analysis		Multivariate analysis		Univariate analysis		Multivariate analysis
	HR (95% CI)	P value	HR (95% CI)	P value	HR (95% CI)	P value	HR (95% CI)	P value
Age
≤ 53	Ref		Ref		Ref		Ref
> 53	0.88 (0.73–1.06)	0.181	0.91 (0.75–1.11)	0.366	1.04 (0.83–1.29)	0.758	1.09 (0.86–1.39)	0.475
PNI
Low	Ref		Ref		Ref		Ref
High	0.71 (0.58–0.87)	< 0.001	0.87 (0.70–1.07)	0.185	0.62 (0.50–0.78)	< 0.001	0.77 (0.60–0.99)	0.043
SII
Low	Ref		Ref		Ref		Ref
High	1.56 (1.27–1.90)	< 0.001	1.16 (0.93–1.43)	0.188	1.66 (1.29–2.15)	< 0.001	1.34 (1.01–1.78)	0.041
Stage
IIB	Ref		Ref		Ref		Ref
III	3.40 (2.26–5.10)	< 0.001	3.02 (1.98–4.60)	< 0.001	3.38 (2.01–5.69)	< 0.001	3.17 (1.85–5.44)	< 0.001
IV	3.99 (2.51–6.36)	< 0.001	3.08 (1.90–4.99)	< 0.001	4.49 (2.52–8.01)	< 0.001	3.78 (2.09–6.86)	< 0.001
Histology
HGSC	Ref		Ref		Ref		Ref
Others	1.26 (1.01–1.58)	0.040	1.72 (1.37–2.17)	< 0.001	1.46 (1.14–1.88)	0.003	2.03 (1.56–2.64)	< 0.001
Comorbidities
No	Ref		Ref		Ref		Ref
Yes	0.86 (0.66–1.12)	0.255	0.98 (0.74–1.29)	0.862	1.10 (0.82–1.47)	0.538	1.31 (0.96–1.79)	0.090
Family history of cancer
No	Ref		Ref		Ref		Ref
Yes	0.89 (0.68–1.16)	0.400	0.84 (0.64–1.10)	0.198	0.86 (0.62–1.18)	0.339	0.77 (0.56–1.06)	0.113
Lymphadenectomy
No	Ref		Ref		Ref		Ref
Yes	0.58 (0.48–0.71)	< 0.001	0.87 (0.70–1.08)	0.214	0.53 (0.42–0.67)	< 0.001	0.82 (0.64–1.06)	0.134
Residual disease
R0	Ref		Ref		Ref		Ref
R1	1.84 (1.44–2.34)	< 0.001	1.69 (1.32–2.16)	< 0.001	2.15 (1.60–2.89)	< 0.001	1.98 (1.46–2.67)	< 0.001
R2	3.22 (2.50–4.13)	< 0.001	2.62 (2.00–3.44)	< 0.001	3.48 (2.56–4.72)	< 0.001	2.85 (2.05–3.94)	< 0.001

PNI Prognostic Nutritional Index, SII Systemic immune-inflammation index, FIGO International Federation of Gynecology and Obstetrics, HGSC High-grade serous carcinoma